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A unique feature of cardiac magnetic resonance is its ability to characterize myocardium. Proton relaxation times, T1, T2, and T2* are a reflection
of the composition of individual tissues, and change in the presence of disease. Research into T1 mapping has largely been focused in the study of
cardiomyopathies, but T1 mapping also shows huge potential in the study of ischaemic heart disease. In fact, the first cardiac T1 maps were used to
characterize myocardial infarction. Robust high-resolution myocardial T1 mapping is now available for use as a clinical tool. This quantitative tech-
nique is simple to perform and analyse, minimally subjective, and highly reproducible. This review aims to summarize the present state of research
on the topic, and to show the clinical potential of this method to aid the diagnosis and treatment of patients with ischaemic heart disease.
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Introduction
Cardiac magnetic resonance (CMR) imaging is the gold standard
imaging technique for cardiac anatomy and function. A unique
feature of CMR is its ability to characterize tissue using proton relax-
ation times, T1, T2, and T2*. These values are largely dependent on
the physical and chemical environments of water protons in tissue.
Using conventional CMR techniques, higher signal intensity with
either T1 weighted sequences using gadolinium contrast agents or
T2 weighted techniques can detect myocardial infarction (MI) or
focal oedema, respectively. However, signal intensity in CMR
images is displayed on an arbitrary scale. Therefore, signals cannot
be quantified or compared between subjects or follow-up examina-
tions in individuals. Visualization of pathology depends on a contrast
existing between ‘normal’ and ‘abnormal’ myocardium.
T1 values are a reflection of the composition of individual tissues,
with each tissue type having a normal intrinsic value. This value
changes in the presence of disease, and therefore can be used to
study and diagnose tissue pathology.1 T1 reflects the mobility of
nuclei (predominantly protons) and how they are bound within
macromolecules. Therefore, it can be used to study macromolecular
content, water binding, and water content. Muscle has an intermedi-
ate value but with inflammation, water content increases and is
matched by an increase in T1.
When T1 is measured on a pixel-by-pixel basis, the resulting T1
values can be visualized as a T1 map. In this map, the signal intensity
of each pixel reflects the absolute T1 value of the underlying voxel.
T1 weighted sequences provide the basis for late gadolinium en-
hancement (LGE) imaging that is now universally used in the detec-
tion of MI and focal lesions of myocarditis and other diseases. The
interest in absolute quantification of T1 values in a clinical setting
has risen recently. Over the last few years, a number of sequences
have been developed which allow robust high-resolution T1
mapping.2,3
History
T1 quantification has been the basis for diagnostic methods since the
beginning of magnetic resonance imaging in the early 1970s. This was
initially driven by the finding that cancerous tissue could be differen-
tiated on the basis of abnormal T1.4 The earliest studies looking at
changes in T1 in the heart were performed in vitro using samples
from dog hearts.5 These showed that T1 increased with ischaemia,
and that the magnitude of increase was related to the duration and
severity of ischaemia. In vivo studies then demonstrated increases in
T1 and T2 with infarction. The first studies to quantify myocardial
T1 in humans with recent MI also detected increased T1 and were
the first to present their findings as a map of the T1 values of the
heart.6 T1 was found to increase within the first hour of ischaemia,7
reach its peak in patients with STEMI between days 8 and 14, before
gradually returning to baseline.8
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Following these early studies, specific techniques were
developed to exploit these changes in tissue oedema. The
short-inversion-time inversion-recovery (STIR) magnetic reson-
ance imaging pulse sequence, which generates high contrast from
both T1 and T2 prolongation in the presence of water, is now
widely used in the detection of myocardial oedema in myocarditis9
and acute MI (Figure 1).10
Ex vivo measurements of T1 are usually based on inversion-
recovery sequences, requiring an interval of at least five times the
T1 to allow for adequate recovery. This technique was used in the
initial studies,6,8 as at the very low field strengths (0.08 T), T1 is
short (305 ms) and acquisition schemes can easily be fitted into the
cardiac cycle. As field strength increases to 1.5 T, myocardial T1
increases to 1000 ms, which exceeds cardiac cycle length in most
patients. As a consequence, conventional acquisition schemes in
these situations cannot be confined to single cardiac cycles and
require long acquisition times. This prevents their use as breath
hold techniques in clinical routine.
T1 quantification in ischaemic heart disease can be divided into
native and post-contrast applications. Native T1 values in this setting
are a reflection of the composite water signal from interstitium and
myocytes, and therefore reflect changes in myocardial water
content. As standard gadolinium contrast agents are extravascular
and extracellular, changes in T1 following contrast administration
reflect gadolinium concentration in the extravascular compartment.
These changes can then be used to estimate extracellular volume
(ECV). To summarize, native T1 detects both intracellular and extra-
cellular changes whereas ECV estimates changes in the myocardial
interstitium (Figure 2).
Native myocardial applications
Myocardial oedema
Ischaemic cell death is characterized by cellular oedema.11 In normal
myocardium, water balance is tightly regulated by cell membrane
function, starling filtration, and lymphatic drainage. Intracellular
water accounts for 79% of total water or about 380 mL/100 g of
dry tissue and varies little between individuals or species.12 The
first studies looking at T1 values in myocardial ischaemia came
from the knowledge that ischaemia results in oedema.13 In fact, the
amount of water present after reflow has been shown to correlate
with myocardial survival in an animal model.14
Cellular oedema occurs within 15 min of coronary occlusion.15
Myocardial water reaches its peak in the first 1–2 h after onset of is-
chaemia16 and is caused bydysfunction of the complex processes that
regulate myocardial water balance. The alterations in cell membrane
function can be simplified into three stages.17 Initially, there is inhib-
ition of the Na+/K+ pump, resulting in an influx of water as it follows
the increased intracellularNa+. The second stage involves sarcolem-
mal transport systems, again allowing intracellular water to increase.
The final stage is of physical disruption of the cell membrane, with an
equilibrium forming between the interior and exterior of the cell.
Reperfusion can worsen oedema and is predominantly deter-
mined by the duration and severity of ischaemia.18 The main
Figure 1: (A) Short-axis STIR image in 52-year-old male 6 days
post-anterior STEMI with localized hyperintensity indicating acute
oedema (arrows). (B) Corresponding Native T1 map demonstrates
a similar area of injury; however, there is a zone with a range of
increased T1 (arrows) reflecting the increasing severity of injury
from epicardium to endocardium.
Figure 2: Images from a patient with recent acute MI resulting from left anterior descending artery occlusion. (A) LGE imaging demonstrating
apical and apico-septal subendocardial MI. (B) Native T1 map with increased T1 in the apex and apical septum. (C) Post-gadolinium contrast
ECV map shows a range of myocardial injury, the most severe injury being subendocardial. The range of injury in the ECV map can be compared
with the binary infarcted/not-infarcted information in the LGE image. Images courtesy of Martin Ugander MD PhD and Peder So¨rensson MD
PhD, Karolinska Institutet, Stockholm, Sweden in collaboration with Peter Kellman PhD, National Institutes of Health, Bethesda, MD, USA.
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mechanisms are hyperaemia and osmotic changes. Following restor-
ation of arterial flow to ischaemic myocardium blood flow greatly
increases. There is a localized increase in cellular osmolality as high
energy phosphates and macromolecules are broken down.19
Despite the diffusion of these products into extracellular spaces,
intracellular osmolality increases.19 On reperfusion, the hyperosmo-
lar myocardial cells absorb extra fluid across this osmotic gradient.
T1 changes in myocardial infarction
The oedema in myocardial ischaemia and infarction can be detected
by increases in T1. T1 can detect acute MI with a high sensitivity and
specificity.20–22 The cut-off T1 value that demarcates infarcted myo-
cardium from the surrounding oedematous myocardium remains to
be delineated; however, previous studies have demonstrated high ac-
curacy using three20 and two21 standard deviations above mean
values. Whereas most studies have focused on patients with
STEMI, T1 mapping can also identify infarction in patients with non-
STEMI.21 There is a progression in T1 from normal to that of
maximal injury, a finding similar to the peri-infarct zone described
in studies studying MI with contrast agents.23 In acuteMI, T1 increases
are morepronounced in myocardium that will become infarcted than
in myocardium which will be salvaged by reperfusion.24 Following
reperfusion, T1 increases further in infarcted tissue, but remains
unchanged in salvaged myocardium.
Elevated water content also increases T2. T2 weighted imaging has
been used for oedema imaging since the first papers demonstrating
T2 prolongation in MI in dogs25 and humans.26 A difficulty with this
technique is the need for signal uniformity as the increase in T2 asso-
ciated with oedema in acute MI is relatively small—in the order of
15–20 ms.7 The STIR sequence, a technique which uses changes in
both T1 and T2 to obtain contrast, is commonly used to identify
areas of hyperintense signal. However, a number of technical issues
may affect the signal intensity, including choice of coil used, artefacts
from slowflowing blood, slice thickness, and TR.27 As absolute values
are not quantified, contrast depends on the presence of ‘normal’
myocardium. Therefore, diseases that involve diffuse or widespread
disease of the myocardium cannot be identified. T2 mapping may
overcome some of these limitations.28
Native T1 measurement may have some other novel uses.
For example, methemoglobin, formed from thrombus, has a T1
shortening effect.29 This can detect intramyocardial haemorrhage
in MI,30 a marker of adverse cardiac outcomes.
Duration of T1 changes
After restoration of normal myocardial blood flow following a brief
period of ischaemia, the ECG can normalize within seconds and func-
tional changes normalize within 5 min. However, increased intracel-
lular water is present for a much greater period of time. Pathological
studies demonstrate a gradual resolution of intracellular oedema,
typically over 1 month.31 These findings were matched in an early
study which demonstrated that water content was elevated with cor-
responding prolongation of T1 in dogs 3 weeks following MI.7 A T1
mapping study demonstrated increased T1 for up to 2 months after
MI.22 Using the STIR technique, persistent small areas of hyperinten-
sity have been noted up to 6 months after infarction.10 Potential
reasons for persistent oedema include increased wall stress and/or
residual/recurring ischaemia, alterations in drainage of the infarcted
segments or continuing tissue repair.
Post-contrast applications
T1mapping in acutemyocardial infarction
Gadolinium contrast administration shortens myocardial T1. The
volume of distribution for contrast agents is greater in areas of cell
membrane rupture, such as infarction. The increased volume of dis-
tribution for gadolinium agents in infarction shortens the T1 of
infarcted areas to a greater extent than that of normal myocardium.
The difference in T1 can be used to distinguish between normal and
infarcted tissue. This property, used in a non-quantitative manner in
LGE imaging, is the in vivo gold standard method of detecting MI. In
acutely injured myocardium, the higher initial concentration of free
water and therefore elevated native T1 will reduce the net change
in T1 and thus reduce the effective T1-shortening and apparent
contrast enhancement.20
Chronic myocardial infarction
In chronic MI, there is replacement of myocardial cells by scarring or
fibrosis with an increase in extracellular collagen. Importantly, there
is no oedema, as this has resolved in the initial weeks after MI. There-
fore, T1 values are higher than in normal myocardium, but not as high
as in acute MI.20 In some areas of chronic MI areas of lipomatous
metaplasia can be seen, particularly when T1 weighted sequences
are used.32 As fat has a T1 value much lower than myocardium
(230–350 ms), T1 mapping can be used to identify intramyocardial
fat.33
Microvascular obstruction
Native T1 values of areas of microvascular obstruction (MVO) have
been found to be slightly higher than that of remote myocardium, but
lower than the surrounding hyperenhanced area.20,21 This may be
due to reduced blood supply in this area, which limits oedema.
Whereas MI detection using LGE reflects decreased wash-out of
contrast, areas of MVOcan be detected by decreasedwash-in. Gado-
linium will, therefore, have less T1 shortening action in areas of MVO
if T1 times are measured early after contrast administration.
Area at risk
The area at risk (AAR) refers to the hypoperfused myocardium
during coronary occlusion.34 In revascularized myocardium, the rela-
tion between the AAR and the infarct allows us to quantify the
volumeofmyocardiumthat reperfusion successfully salvaged from is-
chaemic death. The AAR can therefore not only be used as a measure
of the severityof ischaemic insult, it could also beused to measure the
efficacy of a treatment. To study these changes, the AAR must be
clearly identified. The unique tissue characterization abilities of
CMR make it a suitable method for identifying the AAR.35
The basis of the identification of the AAR is similar for both T1
mapping and T2 weighted imaging, i.e. protons from increased
water in oedematous myocardium caused by ischaemia are detect-
able by increases in T1 and T2. It has been known for many years
that T1 weighted imaging ex vivo was able to delineate the AAR.36
These findings were recently confirmed in vivo, where the AAR
T1 mapping in ischaemic heart disease 599
 at U
niversitaet Zuerich on Septem
ber 10, 2014
http://ehjcimaging.oxfordjournals.org/
D
ow
nloaded from
 
defined by microspheres closely matched the AAR defined by
increased T1.37 In keeping with the concept of oedema being a
marker of severity of injury, T1 changes can predict myocardial
salvage. It has been found that T1 is higher in myocardium that ultim-
ately goes on to undergo infarction than in salvaged myocardium.24
Mapping techniques, using T1 or T2, have the potential to improve
the objectivity of the AAR imaging.
Extracellular volume
The myocardium is made up of both myocardial cells and their sur-
rounding interstitium. The ECV can increase in myocardial disease,
especially through processes that lead to an accumulationof collagen.
The increase can be diffuse or focal as in the case of infarction. The
gold standard test, myocardial biopsy, has both significant morbidity
and sampling error. T1 mapping can be used to quantify ECV, provid-
ing a non-invasive alternative method of quantifying fibrosis. Extracel-
lular volume not only provides a physiologically intuitive unit of
measurement, increased ECV is strongly associated with adverse
outcomes.38
Post-contrast T1 values alone could be used to estimate the ECV;
however, there are multiple factors that influence post-contrast
myocardial T1. By normalizing myocardial T1 in relation to blood
T1, these factors are minimized. The ECV is calculated using the
change in T1 values in myocardium and blood with contrast, and
the haematocrit. Increased ECV has been found not only in diffuse
myocardial diseases such as aortic stenosis and hypertrophic cardio-
myopathy,39 but also in ischaemic heart disease. In acutely infarcted
myocardium, ECV is increased as a result of cellular breakdown. In
chronic infarction, ECV remains elevated due to the development
of replacement fibrosis. Extracellular volume increases in line with in-
creasing levels of myocardial damage. It has been shown that the ECV
of infarcted myocardium is higher than the ECV in other diseases
causing myocardial fibrosis.40
The ECV can be abnormal even in normal appearing myocardium
in patients with ischaemic cardiomyopathy.41 Extracellular volume
increases with worsening left ventricular function. This correlates
with pathological findings from explanted hearts of patients with is-
chaemic cardiomyopathy,42 in which interstitial fibrosis in areas
remote from infarction was increased over two-fold in comparison
with controls. Raised ECV has now been found to be a marker of
adverse short-term outcomes in a wide range of patients.38
It canbe shownthat theECVof salvagedmyocardium ishigher than
that of the remote myocardium as a result of extracellular oedema.
Extracellular volume can delineate the AAR from infarcted and
normal myocardium.43 The post-contrast T1 in the AAR signal inten-
sity differs less than 2SD from the remote myocardium (50 ms),
and is therefore difficult to detect using LGE alone. The combination
of native and post-contrast images demonstrates that the ECV in the
AAR is significantly elevated from remote myocardium.
Technical aspects
T1 mappinguses multiple scanswith varying degreeof signal recovery
in order to calculate T1 values on a pixel-by-pixel basis, from which a
parametric image can be reconstructed. Pixel intensities in these
images correspond toT1 values. This can then be presented as a grey-
scale or colour map of the myocardium.
To produce raw data with varying degree of signal recovery, most
T1 mapping pulse sequences acquire images at different delay time
following a 1808or 908prepulse (inversion recoveryor saturation re-
covery, respectively). Inversion pulses can only be used when the
signal has sufficiently recovered from all preceding experiments. In
order to avoid long waiting times, clinical inversion recovery-based
techniques (e.g. modified Look–Locker inversion recovery,
MOLLI2) are based on the method that was introduced by Look
and Locker44 and acquire data at multiple time points following one
inversion pulse. Inversion pulses provide higher dynamic range than
saturation pulses, but the necessity to use multiple-readout
schemes introduces a certain degree of heart rate dependence,
which becomes relevant at high flip angles (.358 in balanced
steady-state free precession) and high heart rates (.100 bpm20).
Saturation pulses provide lower dynamic range to start with but,
when carried out separately for each raw image, allow for using
high flip angles (e.g. 708) without heart rate dependence.45 As a
result, both approaches exhibit different levels of accuracy and preci-
sion. An in-depth discussion of technical aspects and on-going tech-
nical development is beyond the scope of this manuscript but can be
found in the consensus document on myocardial T1 mapping and
ECV quantification by the T1 Mapping Development Group.46
Technical factors affecting T1
Factors that influence T1 itself include cardiac phase and field
strength.46 The measured T1 value will reflect the T1 of blood in
the myocardium in addition to thatof the myocardium. As myocardial
blood flow occursprimarily during diastole, the phase in which the T1
is measured, systole or diastole, affects T1 measurement. Pre-
contrast, arterial blood T1 is higher than that of myocardium, result-
ing in higher T1 in diastole than systole.47
Only minor differences (a maximum of 2%) have been noted in the
measurement of native T1 between the septal and non-septal
regions.47 No difference, however, has been found between basal,
mid, and apical regions.48
The relatively thin walls of the right ventricle are technically chal-
lenging to assess; however as spatial resolution improves, T1
mapping could also identify right ventricular injury.
Future potential of T1 mapping in
ischaemic heart disease
T1 mapping provides a quantitative method to complement both
oedema imaging (e.g. STIR) and infarct imaging (LGE). An advantage
of T1 mapping is thatby using a quantitative technique, both intra- and
interobserver agreement are very high.47,48
The data provided by native and post-contrast T1 mapping could
help in the diagnosis of patients with acute chest pain, distinguishing
acute coronary syndromes from myocarditis and Takotsubo cardio-
myopathy,49 and acute from chronic infarction. Furthermore, ECV
could aid in the differentiation of ischaemic and non-ischaemic
heart disease in cases of uncertainty.41
There is considerable evidence that increased ECV is a final
common pathway in many kinds of myocardial disease.42 Even in MI
patients, myocardium that appears ‘normal’ on LGE imaging can
have increased ECV. Not only does this impact on the mechanical
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and electrical function of the heart,50,51 it can predict mortality and
other adverse cardiac events.38 Endomyocardial biopsy is the stand-
ard of reference for quantifying fibrosis, but is an invasive procedure
and prone to sampling error. It is known that the development of
diffuse fibrosis is influenced by neurohormonal factors including
angiotensin-converting enzyme, angiotensin II, catecholamines, and
aldosterone. Standard heart-failure treatments, beta-blockers and
angiotensin-converting enzyme inhibitors, can reduce diffuse myo-
cardial fibrosis.41 Extracellular volume has a low variability across
scans, and could be a biomarker in clinical trials.52 Extracellular
volume could non-invasively, serially, and quantitatively assess fibro-
sis in the non-infarcted myocardium as a potential endpoint for
pharmacological intervention in heart failure, using small groups of
patients, greatly reducing trial costs. Looking to the future, the use
of CMR tissue characterization techniques in clinical trials as surro-
gate, mechanistic, and secondary endpoints may increase.
In chronic ischaemic heart disease, standardized T1 thresholds or
ECV values could detect and automatically quantify MI. In addition,
the injury could be analysed, looking for MVO and myocardial haem-
orrhage and studying the peri-infarct zone. This could help the pre-
diction of cardiac events; for instance, some studies have found that
MVO is a predictor of adverse outcomes. The peri-infarct zone is po-
tentially importantpathophysiological substrate forarrhythmias. Pre-
sumptively normal myocardium has been used in prior studies to
differentiate the infarct core (e.g. more than three standard devia-
tions) from the heterogeneous peri-infarct zone, containing viable
myocardium (e.g. between two and three standard deviations).
This border zone may provide a substrate for ventricular tachycardia
and suddencardiacdeath.23 T1 mapping can identify this zoneandpo-
tentially be used in the study of ventricular arrhythmia.
Several CMR techniques can be used in the evaluation of myocar-
dial viability. T1 mapping provides an alternative to the most fre-
quently used method using LGE percentage of transmurality.53 In
this way, the percentage of infarction in each voxel can be calculated.
This allows for automatic quantification of myocardial infarction with
higher accuracy and lower variability than a simple infarcted/
not-infarcted algorithm.
Coronary microembolization is a frequent complication during
PCI. As LGE using semi-automated thresholding underestimates
myocardial damage,54 T1 mapping techniques could identify areas
of reversible and irreversible injury with the aim of improving revas-
cularization techniques. In the field of research, it offers a quantitative
alternative to T2 weighted methods to measure the AAR from MI in
NSTEMI and STEMI.
Conclusion
T1 quantification has a long history in the study of ischaemic heart
disease. Recent image sequence developments allow T1 values to
be quickly and reproducibly quantified on a pixelwise basis and pre-
sented as T1 maps using clinical MR systems. Oedema from acute
myocardial ischaemia and replacement fibrosis in chronic MI can be
accurately detected and quantified. The combination of native and
post-contrast images can detect not only MI and the AAR, but also
demonstrate a range of myocardial injury by measuring ECV.
The precise role of T1 mapping in the evaluation of ischaemic heart
disease remains to be defined, however its broad potential, and the
fact it is a quantitative measurement show much promise for the
future.
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